Fig. 7From: Development of a novel immune-related lncRNA prognostic signature for patients with hepatocellular carcinomaA, B Waterfall maps of twenty mutated genes in high−/low-risk group. C-E The relationship between targeted therapy, chemotherapy and IC50 in high−/low-risk groupBack to article page